Comparative Pharmacology
Head-to-head clinical analysis: ARIMIDEX versus AROMASIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIMIDEX versus AROMASIN.
ARIMIDEX vs AROMASIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aromatase inhibitor; inhibits conversion of androgens to estrogens by binding to aromatase enzyme, reducing estrogen levels in tissues.
Irreversible steroidal aromatase inhibitor that binds to the aromatase enzyme, leading to its permanent inactivation via covalent modification. This reduces estrogen biosynthesis (primarily in peripheral tissues) by inhibiting conversion of androgens to estrogens.
1 mg orally once daily
25 mg orally once daily after a meal
None Documented
None Documented
Terminal elimination half-life ~50 hours (range 30-60 hours); supports once-daily dosing.
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) for exemestane, supporting once-daily dosing. Steady state achieved within 7 days.
Primarily hepatic metabolism via N-dealkylation and glucuronidation; ~80% excreted in feces, <10% unchanged in urine.
Primarily hepatic metabolism via CYP3A4 and aldoketoreductases, with 60-70% of metabolites excreted renally and 30-40% via feces. Less than 1% excreted unchanged in urine.
Category C
Category C
Aromatase Inhibitor
Aromatase Inhibitor